Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) can increase pathological response rate (pCR) (6–8) and improve overall survival (OS) in GC (9–11). The gene discussed is PDCD1; the disease is gastric cancer.